Company Filing History:
Years Active: 2020-2024
Title: Innovations of Inventor Hong Hoi Ting in Cancer Research
Introduction
Hong Hoi Ting, an accomplished inventor based in Shanghai, China, has made significant contributions to the field of cancer research through his remarkable innovations. With a total of 5 patents to his name, he has focused on developing advanced methodologies for diagnosing and treating tumors, particularly those that are Her2 positive.
Latest Patents
His latest patents showcase cutting-edge advancements, including an "Anti-Her2 nanobody and coding sequence and use thereof." This patent details a nanobody specifically designed to combat the human epidermal growth factor receptor-2 (Her2/ERBB2). The invention includes the nanobody, the gene sequence encoding it, an expression vector, and a host cell that can express the nanobody, along with methods for its production and application. Additionally, he has patented the "Use of radiolabeled nanobody in prognosis and diagnosis of cancer." This invention focuses on an immunoconjugate for detecting the PD-L1 molecule. The immunoconjugate features a specific anti-PD-L1 nanobody linked to a radionuclide for non-invasive cancer detection, demonstrating high specificity, accuracy, and a minimized radiation dose.
Career Highlights
Hong Hoi Ting's work is emblematic of the transition toward more targeted and effective cancer therapies. His innovative approaches not only advance the understanding of tumor biology but also pave the way for improved diagnostic techniques. Through his patents, he has illuminated pathways for future research and clinical applications.
Collaborations
At Nanomab Technology Limited, where he is currently employed, Hong collaborates with noteworthy colleagues such as Chung Lim Wong and Wenhua Huang. Their combined expertise enhances the potential for further breakthroughs in nanobody research and its applications in oncology.
Conclusion
Hong Hoi Ting stands out as a pivotal figure in the realm of cancer research and innovation. His patents reflect a robust commitment to transforming the landscape of cancer diagnostics and treatment. As his work continues to evolve, it promises to hold substantial implications for improving patient outcomes and advancing medical technology.